Skip to main content
Article thumbnail
Location of Repository

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder

By P Sobocki, M Ekman, A Ovanfors, R Khandker and B Jönsson
Topics: Original Articles
Publisher: Blackwell Publishing Ltd
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2007). A ˚gren H et al. Health-related quality-of-life measured with EQ-5D in patients treated for depression in primary care. Value Health
  2. (2006). A ˚gren H et al. Model to assess the costeffectiveness of new treatments for depression.
  3. (2007). A ˚gren H et al. Resource-use and costs associated with patients treated for depression in primary care.
  4. (2006). A ˚gren H et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression.
  5. (2000). American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder (revision).
  6. (2001). Assessment of clinical guidelines for continuation treatment in major depression. Value Health
  7. (2005). Betalningsviljan fo ¨r ett kvalitetsjusterat levnadsa ˚r – en pilotstudie. Institutet fo ¨rH a ¨lsoekonomi. (accessed
  8. British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.
  9. (2003). Clin Psychiatry
  10. (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry
  11. (2001). Continuation and maintenance therapy in depression.
  12. (1998). Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics
  13. (2003). Cost of lost productive work time among US workers with depression. JAMA
  14. (1995). Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials
  15. (2008). Cost-effectiveness of maintenance treatment in depression ª
  16. (2000). Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder. Value Health
  17. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the
  18. (2003). General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2).
  19. (1999). Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess
  20. (2003). Health services need knowledge of how the public values health. La ¨kartidningen
  21. (2000). Multiple recurrences of major depressive disorder.
  22. (2003). Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy.
  23. (1997). Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confi-dence interval estimation. Health Econ
  24. (2008). Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000; 22: 153–62. Cost-effectiveness of maintenance treatment in depression 631 ª
  25. (1999). Recurrence after recovery from major depressive disorder during 15 years of observational follow-up.
  26. (2003). Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci
  27. (2006). Recurrence prevention: Efficacy of Two Years of Maintenance Treatment with Venxalafine XR in Patients with Recurrent Unipolar Major Depression.
  28. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet
  29. (2005). Remission from depression: a review of venlafaxine clinical and economic evidence. Pharmacoeconomics
  30. (2006). Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a metaanalysis of head-to-head trials. Curr Med Res Opin
  31. (2006). Statistical Year Book of Sweden.
  32. (1997). Suicide as an outcome for mental disorders. A meta-analysis.
  33. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res
  34. (2004). The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry
  35. The economic burden of depression in the United States: how did it change between
  36. (1999). The effect of episodes on recurrence in affective disorder: a case register study.
  37. (2004). The Swedish Council on Technology Assessment in Health Care (SBU). Behandling av depressionssjukdomar – En systematisk litteraturo ¨versikt (Treatment of depression).
  38. (1960). The value of medical spending in the United States,
  39. Treatment of Major Depression.
  40. (1998). US and UK health economics: two disciplines separated by a common language? Health Econ
  41. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health
  42. (2005). Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Mak

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.